| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5619125 | Nutrition, Metabolism and Cardiovascular Diseases | 2016 | 30 Pages |
Abstract
The available evidence is insufficient to establish any of the proposed mechanisms of cardiovascular action of empagliflozin. While awaiting for the results of ongoing clinical studies with other SGLT2 inhibitors, the most promising putative mechanisms still deserve to be confirmed with specifically designed, yet unavailable, pre-clinical studies.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
M. Luconi, L. Raimondi, A. Di Franco, E. Mannucci,